Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Study Phase : Phase II
Recipient : Hyloris Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyloris Announces Enrolment of First Patient in a 4-Arm Clinical Trial of Alenura(TM)
Details : Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.
Product Name : Alenura
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Highest Development Status : Phase II
Recipient : Hyloris Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 21, 2023
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Study Phase : Phase II
Sponsor : Hyloris Pharmaceuticals
Deal Size : $6.7 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Vaneltix will be responsible for the further development, manufacturing, regulatory affairs and commercialisation of AlenuraTM in collaboration with Hyloris.
Product Name : Alenura
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2021
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Highest Development Status : Phase II
Sponsor : Hyloris Pharmaceuticals
Deal Size : $6.7 million
Deal Type : Collaboration